Akero Therapeutics, Inc.
AKRO
$48.43
$0.400.83%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.69% | 29.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.01% | 3.66% | |||
| Operating Income | 0.01% | -3.66% | |||
| Income Before Tax | 0.31% | -1.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.31% | -1.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.31% | -1.00% | |||
| EBIT | 0.01% | -3.66% | |||
| EBITDA | 0.01% | -3.68% | |||
| EPS Basic | 4.06% | 9.37% | |||
| Normalized Basic EPS | 4.06% | -5.92% | |||
| EPS Diluted | 4.06% | 9.37% | |||
| Normalized Diluted EPS | 4.06% | -5.92% | |||
| Average Basic Shares Outstanding | 3.90% | 11.45% | |||
| Average Diluted Shares Outstanding | 3.90% | 11.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||